Aerius Generic Drug
Therapeutic class: Allergology
Active ingredients: Desloratadine
laboratory: Biogaran

Coated tablet
Case of 30
All forms


DESLORATADINE ALMUS 5 mg film-coated tablets are indicated for the symptomatic treatment of:

· Allergic rhinitis (see section on Pharmacodynamic properties ),

· Urticaria (see section 5.1 ).

Dosage DESLORATADINE ALMUS 5 mg Film-coated tablet Case of 30

Adults and adolescents (12 years and older): once a day, at least once a day, together with meals to relieve symptoms associated with allergic rhinitis (including allergic rhinitis). persistent and persistent) and with urticaria (see section 5.1 Pharmacodynamic properties ).

In adolescents aged 12 to 17, the experience of using desloratadine in clinical efficacy studies is limited (see sections 4.8 and 5.1 ).

Interallitic allergic rhinitis (presence of symptoms over a period of 4 days per month or over a period of less than 4 minutes) should be managed according to the assessment of antecedents. of the disease of the patient, the patient can be questioned after the disappearance of symptoms, and restored to their reappearance.

In persistent allergic rhinitis (presence of symp- toms over a period of 4 days or more per muscle and for more than 4 minutes), continuous treatment may be given to patients during periods of allergenic exposure.

Against indications

Hypersensitivity to the active substance, to any of the excipients, or to loratadine.

Adverse effects Desloratadine Almus

In clinical trials conducted in allergic rhinitis and idiopathic chronic urticaria, at the recommended dose of 5 mg daily, adverse events were reported in 3% more patients than those treated with placebo. The most common adverse events reported with an incidence greater than placebo were: asthenia (1.2%), dry mouth (0.8%) and headache (0.6%). In a clinical study in 578 adolescent patients aged 12 to 17 years, the most common adverse event was headache; it occurred in 5.9% of patients treated with desloratadine and in 6.9% of patients receiving placebo. Other side effects that have been reported very rarely since marketing are listed in the following table:

Psychiatric disorders


Nervous system disorders

Vertigo, so m nolence, inso mia, hy peractivity ps yc ho m otrice, convulsions.

Heart conditions

Tach y cardia, palpitations.

Gastrointestinal disorders

Abdominal pain, nausea, vomiting, spepsia, diarrhea.

Hepatobiliary disorders

Increases in liver enzymes, increased bilirubin, hepatitis.

Musculoskeletal and systemic disorders

M y algie.

General disorders

Persistence reactions (such as anaphylaxis, angioedema, sputum, pruritus, rash, and urticaria).

Popular Posts